Vor Biopharma Inc. (VOR) - What Are Investment Firms Thinking About This Stock?

Key Points

• Analyst sentiment is moderately positive: Vor Biopharma has a consensus “Moderate Buy” rating, with five buys, two strong buys, and three holds. The average 12-month price target is $38.00, well above the reported share price of $18.94.
• Recent financial results fell short of expectations: The company reported a quarterly loss of $0.80 per share versus the $0.69 consensus estimate, and analysts expect a full-year loss of approximately $2.56 per share.
• Institutional ownership remains high: Hedge funds and other institutional investors own 97.29% of the stock, with several major investors recently increasing or initiating positions. Vor is developing engineered stem-cell therapies, including its lead VOR33 program for acute myeloid leukemia.

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) has been given a consensus rating of "Moderate Buy" by the ten ratings firms that are presently covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $38.00.

VOR has been the subject of several recent research reports. Weiss Ratings raised Vor Biopharma from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Monday, September 14th. Wedbush upped their price objective on Vor Biopharma from $18.00 to $27.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 12th. William Blair started coverage on Vor Biopharma in a research report on Wednesday. They set an "outperform" rating on the stock. Citigroup upgraded Vor Biopharma to a "strong-buy" rating in a research note on Thursday, October 15th. Finally, Wall Street Zen upgraded shares of Vor Biopharma from a "sell" rating to a "hold" rating in a report on Saturday, August 15th.

Vor Biopharma Price Performance

Shares of NASDAQ:VOR opened at $18.94 on Friday. Vor Biopharma has a 52 week low of $6.50 and a 52 week high of $28.66. The firm has a 50 day moving average of $21.22 and a 200 day moving average of $18.42.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.11). Equities research analysts predict that Vor Biopharma will post -2.56 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of VOR. Engineers Gate Manager LP lifted its position in Vor Biopharma by 37.5% during the second quarter. Engineers Gate Manager LP now owns 36,951 shares of the company's stock valued at $680,000 after acquiring an additional 10,071 shares during the last quarter. Braidwell LP boosted its stake in Vor Biopharma by 22.8% in the second quarter. Braidwell LP now owns 573,104 shares of the company's stock valued at $10,551,000 after acquiring an additional 106,330 shares in the last quarter. Wellington Management Group LLP acquired a new stake in Vor Biopharma in the second quarter valued at approximately $499,000. Bank of New York Mellon Corp acquired a new stake in Vor Biopharma in the second quarter valued at approximately $1,799,000. Finally, Bank of America Corp DE grew its holdings in Vor Biopharma by 28,408.1% in the first quarter. Bank of America Corp DE now owns 112,892 shares of the company's stock worth $2,014,000 after purchasing an additional 112,496 shares during the last quarter. Hedge funds and other institutional investors own 97.29% of the company's stock.

Vor Biopharma Company Profile

Vor Biopharma Inc is a clinical-stage biotechnology company focused on developing engineered hematopoietic stem cell therapies for the treatment of cancer, particularly blood cancers. The company combines gene-editing technologies with targeted immunotherapies to address limitations associated with conventional cancer treatments.

Vor's platform is designed to create engineered hematopoietic stem cells that can protect healthy blood-forming cells from targeted therapies. Its lead program, VOR33, is an investigational CD33-edited hematopoietic stem cell therapy intended to support the use of CD33-targeted treatments in patients with acute myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.